Compare General Dynamics Corporation (GD) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Moderna, Inc. — how do they compare? General Dynamics Corporation trades at $368.01 (market cap $98.88B), while Moderna, Inc. trades at $65.15 (market cap $27.09B). The key difference: General Dynamics Corporation is far larger — about 3.7× Moderna, Inc.'s market cap, and General Dynamics Corporation pays a 1.74% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| GD | MRNA | |
|---|---|---|
Market Cap | $98.88B | $27.09B |
Sector | Industrials | Health |
52-Week High | $376.88 | $81.80 |
52-Week Low | $297.05 | $22.36 |
Enterprise Value | $105.06B | $23.19B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $369.5, down 0.88% on the day, with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $4.10 surpassing the $3.67 expectation. Revenue growth is robust, reaching $52.55B in 2025, while net income margin improved to 8.07%. The stock is supported by a substantial $130.8 billion backlog and a consistent dividend, with the next payment of $1.59 scheduled for August 7, 2026.
The outlook for GD is positive, driven by strong defense spending tailwinds, naval contract dominance, and consistent earnings beats. Investment opportunities include exposure to growing submarine and C5ISR markets. Key risks involve execution on massive backlogs, potential defense budget volatility, and valuation metrics (P/E of 23.01) that are above some industry peers, requiring sustained growth to justify.
Moderna (MRNA) trades at $67.44, showing modest daily gains amid a bullish technical signal. The company continues to beat earnings expectations despite reporting significant net losses, with revenue declining from pandemic peaks to $1.92B in 2025. Recent positive developments include EU RSV vaccine contracts, Phase 1 cancer trial initiation, and FDA advisory panel support for its mRNA flu vaccine, driving recent stock momentum.
While Moderna's pipeline expansion beyond COVID-19 shows promise with oncology and rare disease applications, substantial financial risks persist with negative profit margins and cash burn. Analyst consensus remains cautious with a $49 price target below current levels, reflecting concerns about revenue sustainability versus pipeline execution risks and valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
